Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Clinical, Allergological and Otorhinolaryngological Characteristics of Rhinitis in a Small Real-Life Cohort: a Descriptive Pilot Study.

Maedica·2026
Same journal

The Prevalence and Risk of Polycystic Ovarian Syndrome (PCOS) in Women with Epilepsy: a Systematic Review and Meta-Analysis.

Maedica·2026
Same journal

Validation of the ASALT Score for Predicting Biliary Etiology in Acute Pancreatitis: a Single-Center Study of 441 Patients.

Maedica·2026
Same journal

Acute Isolated Dislocation of the Trapeziometacarpal Joint: Report of Two Clinical Cases.

Maedica·2026
Same journal

Evaluation of Vitamin B12 Levels in Chronic Spontaneous Urticaria Patients and Correlation with Severity of Disease.

Maedica·2026
Same journal

Robotic Guidance and Optical Navigation for Precision Implant Placement: a Prospective Comparative Clinical Study.

Maedica·2026

Related Experiment Video

Updated: Jul 19, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K

Current Knowledge of Heart Failure with Preserved Ejection Fraction.

Leonida Gherasim Md PhD1

  • 1Professor, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania Cardiology, University Hospital of Bucharest, Romania.

Maedica
|August 17, 2023
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) is common in older adults and challenging to treat. Identifying HFpEF phenotypes aids understanding and therapeutic development, though results remain uncertain.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Related Experiment Videos

Last Updated: Jul 19, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is the most prevalent form of heart failure, particularly affecting the elderly.
  • Diagnosis relies on clinical data, imaging (left ventricular diastolic dysfunction), and biochemical markers (elevated natriuretic peptide levels with ejection fraction ≥50%).

Discussion:

  • Several distinct HFpEF phenotypes have been identified based on etiological and pathophysiological characteristics.
  • Understanding these phenotypes enhances knowledge of specific pathogenic mechanisms driving HFpEF.
  • Therapeutic strategies, including pharmacological and non-pharmacological agents, are being explored for these phenotypes, but outcomes are currently uncertain.

Key Insights:

  • HFpEF diagnosis requires a combination of clinical assessment, echocardiographic findings of diastolic dysfunction, and elevated natriuretic peptides.
  • Phenotyping HFpEF is crucial for elucidating underlying disease pathways and guiding targeted treatment development.
  • Despite advances in understanding HFpEF subtypes, effective therapeutic interventions remain a significant challenge.

Outlook:

  • Further research into HFpEF phenotypes may lead to more personalized and effective treatment approaches.
  • Continued investigation into novel pharmacological and non-pharmacological therapies is essential for improving patient outcomes.
  • The development of targeted therapies based on specific HFpEF phenotypes holds promise for future clinical practice.